QNRX News and Press, Quoin Pharmaceuticals Ltd. From 03/05/24

ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering o...

2024-03-04 09:06:31 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX ) reported, this morning, that the U.S. Food and Drug Administration (FDA) cleared the Company to recruit teen subjects aged 14 years and older into its two ongoing cli...

Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development represents the first e...

2024-02-12 17:28:31 ET More on Quoin Pharmaceuticals Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharmaceuticals Read the full article on Seeking Alpha ...

ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan dise...

Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., Dec. 13, 20...

2023-11-09 10:59:32 ET More on Quoin Pharmaceuticals Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for ...

2023-11-09 10:51:04 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Gordon Dunn – Chief Financial Officer Michael Myers – Chief Executive Officer Conference Call Participants ...

Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator skin scoring system and patient global assessment ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...